Search
Iloperidone
go.drugbank.com/drugs/DB04946ApprovedInvestigationalIloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009. … [A3024] It is considered to be a second-generation antipsychotic drug [A263552] with multiple receptor binding profile, although it shows high affinity towards 5-HT<sub>2A</sub> and dopamine D2 receptors
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMetamizole
go.drugbank.com/drugs/DB04817ApprovedInvestigationalWithdrawnApprovals of the NDA's for metamizole drug products were withdrawn on June 27, 1977 (see the Federal Register of June 17, 1977, 42 FR 30893).
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP3A InducersMaralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigationalMaralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like [odevixibat]. … [L38834] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalFor these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. … On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesGemifloxacin
go.drugbank.com/drugs/DB01155ApprovedInvestigationalGemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseDextroamphetamine
go.drugbank.com/drugs/DB01576ApprovedIllicitInvestigationalDextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]
Categories: Psychostimulants, Agents Used for ADHD and Nootropics, Cytochrome P-450 SubstratesPD-168393
go.drugbank.com/drugs/DB07662ExperimentalPD-168393 is an epidermal growth factor receptor inhibitor.
Etonogestrel
go.drugbank.com/drugs/DB00294ApprovedInvestigationalEtonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and F...
Categories: Hormonal Contraceptives for Systemic Use, Cytochrome P-450 SubstratesProducts: Implanon NXT 68 mg Implantat zur subkutanen AnwendungEthotoin
go.drugbank.com/drugs/DB00754ApprovedEthotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersAlimemazine
go.drugbank.com/drugs/DB01246ApprovedVet approvedWithdrawnA phenothiazine derivative that is used as an antipruritic.
Categories: Antihistamines for Systemic Use